Answers are grounded in this paper and cite their sources.
Patients with relapsed or refractory multiple myeloma (RRMM) previously exposed to proteasome inhibitors, immunomodulatory drugs, anti-CD38 monoclonal antibodies, and anti-B-cell maturation antigen (BCMA) therapies, defined as quadruple-class exposed (QCEx), face poor prognoses and limited therapeutic options. This study retrospectively tracked treatment journeys of this population across lines of therapy (LOTs), documenting disease characteristics and clinical outcomes using deidentified electronic health record data from Flatiron Health database (January 2011-July 2025). In total, 21,112 patients with MM were identified; of these, 683 had QCEx RRMM, 241 initiated a subsequent (index) therapy, and 121 died before receiving an index therapy. At index, patients had a median 5 prior LOT (range, 1-14), 49.8% exhibiting quadruple-class refractory disease. The median age was 67 years (range, 37-85). The most common index regimens were G protein-coupled receptor class C group 5 D (GPRC5D) bispecific antibodies (17.8%), BCMA-targeted (11.6%), and chemotherapy-based (9.5%) regimens. Median event-free and overall survival were 5.0 months (95% CI, 4.0-5.8) and 15.6 months (95% CI, 12.2-22.0), respectively. Approximately 25% died before advancing to each additional LOT. These findings highlight the profound clinical unmet need among patients with QCEx RRMM. Early intervention with novel and effective therapies is crucial to improving outcomes.
No takes yet. Share an insight, caveat, or question.
Hansen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: